SBI Securities’s Dianthus Therapeutics DNTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.23K Buy
14
+13
+1,300% +$1.35K ﹤0.01% 2781
2026
Q2
$97 Sell
1
-20
-95% -$1.75K ﹤0.01% 3520
2026
Q1
$1.76K Buy
21
+19
+950% +$1.1K ﹤0.01% 2461
2025
Q4
$82 Hold
2
– – ﹤0.01% 3464
2025
Q3
$79 Buy
2
+1
+100% +$26 ﹤0.01% 3585
2025
Q2
$19 Hold
1
– – ﹤0.01% 3922
2025
Q1
$18 Sell
1
-6
-86% -$132 ﹤0.01% 3871
2024
Q4
$153 Buy
+7
New +$180 ﹤0.01% 3331

Other funds holding DNTH

SBI Securities's DNTH Position: Q3 2026 in Review

SBI Securities increased its Dianthus Therapeutics (DNTH) stake by 1,300% in Q3 2026, buying an estimated $1.35K and bringing the position to 14 shares worth $1.23K. The position accounts for ﹤0.01% of the portfolio, ranked #2781.

SBI Securities first reported a position in DNTH in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.76K in Q1 2026. 275 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • SBI Securities held 14 shares of Dianthus Therapeutics worth $1.23K as of Q3 2026.
  • SBI Securities bought 13 Dianthus Therapeutics shares in Q3 2026, an estimated $1.35K.
  • Dianthus Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #2781 holding.
  • SBI Securities first reported a position in Dianthus Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • SBI Securities's Dianthus Therapeutics position peaked at $1.76K in Q1 2026.
  • 275 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.